

National Medical Care Company (Care) posted net income of SAR 16.6mn (SAR 0.37 EPS), in line with our estimate of SAR 15.8mn and above the consensus estimate of SAR 13.4mn. Revenue exceeded our estimates due to higher than expected average revenue per bed. The GP margin expansion can be attributed to cost rationalization measures undertaken by the company. We maintain our recommendation of “**Neutral**” on the stock with a TP of **SAR 58.60/share**.

- Care posted net income of SAR 16.6mn in Q3-19 (EPS of SAR 0.37), in line with AJC's estimate of SAR 15.8mn and above the market consensus estimate of SAR 13.4mn. The net income increase of 45.4% Y/Y was driven by reduced operating costs (manpower, consumables and pharmaceuticals) and lower provision for credit losses. The reduced operating costs can be ascribed to cost rationalization measures undertaken by the company. The surge in revenue and continued effective utilization of resources also contributed to the rise in net income. A higher zakat charge partially offset the increase achieved from items mentioned above.
- Care's sales in Q3-19 stood at SAR 173.5mn, reflecting a decrease of 1.6% Y/Y, above our estimate of SAR 158.6mn. The revenue decline was mainly due to the lower number of patients, especially those relating to the Occupational Hazard Contract with GOSI, and a drop in Ministry of Health (MoH) cases accepted by the company.
- Gross profit stood at SAR 40.1mn, indicating a rise of 20.9% Y/Y. The GP Margin climbed to 23.1% in Q3-19 from 18.8% in Q3-18 against our estimate of 21.5%. Cost rationalization measures led to lower operating costs (manpower, pharmaceuticals and consumables), which boosted the GP Margin.
- Operating profit stood at SAR 23.0mn, depicting an increase of 30.8% Y/Y. Net OPEX grew 9.8% Y/Y to SAR 17.1mn in Q3-19 compared to our estimates of SAR 12.4mn and SAR 15.6mn posted in Q3-18.

AJC view: Care's net profit was in line with our expectations. However, the expansion in the GP and operating margins beat our expectations, and represent positive signs for the company going forward. Despite lower volume of patients, the decline in Y/Y revenue was minimal which is noteworthy. We maintain our EPS estimate for FY19 at SAR 1.65, but tweak our revenue estimate for the year to SAR 695.7mn from SAR 674.1mn. In the medium term, improvement in margins through cost-control measures, revenue growth through capacity addition at CNH, and benefits accruing from NMC Health's expertise are expected to be the key drivers of the company's growth. A high percentage of receivables from government and semi-government entities (66% of receivables in FY18) remain a major concern for the company. Our weighted average value is based on the DCF and relative valuation technique (a peer group EV/EBITDA matrix), where 70% weight is assigned to the DCF and 30% to the relative valuation technique. The terminal growth rate is taken at 3.0%, while the two-year weekly beta is 0.80 and average WACC is 6.8%. We maintain our recommendation of “**Neutral**” on Care with a TP of **SAR 58.60/share**.

Results Summary

SARmn	Q3-18	Q2-19	Q3-19	Change Y/Y	Change Q/Q	Deviation from AJC Estimates
Revenue	176.4	169.9	173.5	-1.6%	2.1%	9.4%
Gross Profit	33.2	38.3	40.1	20.9%	4.8%	17.6%
<i>Gross Margin</i>	<i>18.8%</i>	<i>22.5%</i>	<i>23.1%</i>	-	-	-
EBIT	17.6	20.3	23.0	30.8%	13.7%	5.8%
Net Profit	11.4	13.8	16.6	45.4%	20.5%	5.4%
EPS	0.26	0.31	0.37	-	-	-

Source: Company Reports, Aljazira Capital

Neutral

Target Price (SAR) **58.60**

Upside / (Downside)* **26.5%**

Source: Tadawul *prices as of 06th of November 2019

Key Financials

SARmn (unless specified)	FY17	FY18	FY19E
Revenues	855.1	763.8	695.7
Growth %	-5.1%	-10.7%	-8.9%
Net Income	85.3	62.2	74.1
Growth %	69.7%	-27.1%	19.1%
EPS	1.90	1.39	1.65

Source: Company reports, Aljazira Capital

Key Ratios

	FY17	FY18	FY19E
Gross Margin	22.9%	21.8%	23.4%
Net Margin	10.0%	8.1%	10.6%
P/E	22.9x	36.3x	31.8x
P/B	2.0x	2.3x	2.3x
EV/EBITDA (x)	11.8x	13.0x	12.4x


Source: Company reports, Aljazira Capital

Key Market Data

Market Cap (bn)	2.1
YTD %	-8.0%
52 Week High/ Low	41.00/60.90
Shares Outstanding (mn)	44.9

Source: Company reports, Aljazira Capital

Price Performance



Source: Tadawul, Aljazira Capital

Head of Research

Talha Nazar

+966 11 2256250

t.nazar@aljaziracapital.com.sa



RESEARCH DIVISION

Head of Research
Talha Nazar
+966 11 2256250
t.nazar@aljaziracapital.com.sa

Senior Analyst
Jassim Al-Jubran
+966 11 2256248
j.aljabran@aljaziracapital.com.sa

Analyst
Abdulrahman Al-Mashal
+966 11 2256374
A.Almashal@Aljaziracapital.com.sa

BROKERAGE AND INVESTMENT CENTERS DIVISION

General Manager – Brokerage Services & sales
Alaa Al-Yousef
+966 11 2256060
a.yousef@aljaziracapital.com.sa

AGM-Head of international and institutional brokerage
Luay Jawad Al-Motawa
+966 11 2256277
lalmutawa@aljaziracapital.com.sa

AGM-Head of Qassim & Eastern Province
Abdullah Al-Rahit
+966 16 3617547
aalrahit@aljaziracapital.com.sa

AGM-Head of Sales And Investment Centers
Central Region, & acting head Western and Southern Region Investment Centers
Sultan Ibrahim AL-Mutawa
+966 11 2256364
s.almutawa@aljaziracapital.com.sa

RESEARCH DIVISION

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING TERMINOLOGY

- Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
- Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
- Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
- Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. This report has been written by professional employees in Al-Jazira Capital, and they undertake that neither them, nor their wives or children hold positions directly in any listed shares or securities contained in this report during the time of publication of this report, however, The authors and/or their wives/children of this document may own securities in funds open to the public that invest in the securities mentioned in this document as part of a diversified portfolio over which they have no discretion. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Corporate Finance | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia. Tel: 011 2256000 - Fax: 011 2256068